Global Diphenhydramine Market is segmented By Dosage Forms (Tablets, Injection, Powder, Syrups), By Application (Allergies, Insomnia, Cold, Nausea, Other), By Distribution Channel (Hospital Pharmacy, Pharmacy Stores, Other), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Diphenhydramine Market Size
The global Diphenhydramine Market size was valued US$ XX billion in 2022 and is estimated to reach US$ XX billion by 2029, growing at a CAGR of 2% during the forecast period (2024-2031).
Diphenhydramine is an antihistamine that reduces the effects of natural chemical histamine in the body. Diphenhydramine is used to treat sneezing, runny nose, watery eyes, hives, skin rash, itching, and other cold or allergy symptoms. Diphenhydramine is also used to treat motion sickness, to induce sleep, and to treat certain symptoms of Parkinson's disease.
Diphenhydramine Market Summary
|
Metrics |
Details |
|
Market CAGR |
2% |
|
Segments Covered |
By Dosage Forms, By Application, By Distribution Channel and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other vital insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
To Get a Free Sample Click here
Diphenhydramine Market Dynamics
The global diphenhydramine market growth is driven by the increasing levels of indoor and outdoor pollution, changing lifestyles, poor dietary habits, and rapid urbanization across the world. These factors are driving the growth of the market across the world.
The rising cases of allergies are expected to increase the demand in the forecast period
The rising cases of allergies are expected to increase the demand for diphenhydramine, leading to the high growth of the market over the forecast period. According to the International Study of Asthma and Allergies in Childhood (ISAAC), about 22.1% of young children aged between 13 and 14 years are affected by hay fever, which was globally published in World Allergy Week 2016 fact sheet.
As per the data published by the American College of Allergy, Asthma & Immunology, allergies are the sixth leading cause of chronic illness in the United States, with an annual cost in excess of USD 18 billion, and more than 50 million Americans suffer from allergies each year. There is an increase in the number of people suffering from food allergies among both children and adults, globally. Hence, the increasing burden of allergic diseases is expected to aid the demand for the diphenhydramine market.
Increasing demand for self-medication expected to drive the market growth
There is a gradual demand for self-medication among the masses, owing to the advantage of getting quicker relief and economical treatment at the same time. Diphenhydramine works well for treating allergic rhinitis. They are only available with a prescription. Diphenhydramine is a medicine that helps dry up a runny or stuffy nose. They come as pills, capsules. The gradual acceptance of these products have encouraged key players like Johnson & Johnson to launch new products for self service.
High investment costs in R&D is likely to hinder the market growth
However, this medication may cause blurred vision and may impair thinking or reactions. Taking this medicine with other drugs that make sleepy or slow breathing can worsen these effects. Thus, these side effects make the patient avoid them which in turn hinder the market growth.
COVID-19 Impact Analysis on Diphenhydramine Market
The current COVID‐19 pandemic influences many areas of social life, medical treatments and the way allergy diagnosis and treatment is performed. Allergen‐specific immunotherapy (AIT) is one of the most important treatment options for IgE‐mediated allergies and is based on immunological effects on the diseased patient. This manuscript outlines the EAACI recommendations regarding AIT during the COVID‐19 pandemic and aims at supporting allergists and all physicians performing AIT in their current daily practice with clear recommendations. Thus the growing prevalence of allergies due to the outbreak is driving the growth of the market.
Diphenhydramine Market Segmentation Analysis
The allergies segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)
Diphenhydramine is used for the treatment of allergies, and it is first line of therapy for the same. Increasing levels of indoor and outdoor pollution, changing lifestyle, poor dietary habits, and rapid urbanization across the world are few of the factors due to which patients suffering from allergies are rapidly increasing. As per the International Study of Asthma and Allergies in Childhood (ISAAC), 22.1% of children of age 13- and 14-years experienced hay fever. This high incidence of the targeted patient pool results in propelling the market to a certain extent.
Rising investment patterns in allergy drug development by the manufacturers and research and development of novel allergy immunotherapy (AIT) is expected to further enhance the overall market in the forecast period.
The hospital pharmacy is expected to dominate the diphenhydramine market during the forecast period
The hospital pharmacies held the largest share in the diphenhydramine market. This is mainly owing to increasing number of patients suffering from conditions that are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, the growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment.
Global Diphenhydramine Market Geographical Share
North America region holds the largest market share global diphenhydramine market
North America region is dominating the global diphenhydramine market accounted for the largest market share in 2019. As per the data published by the American College of Allergy, Asthma, & Immunology, allergies are the 6th leading cause of chronic illness in the United States, and every year, more than 50 million Americans suffer from allergies. Thus, the increasing burden of allergic diseases is expected to aid the demand for diphenhydramine drugs and further propel the growth of the market in this region. Moreover, the increasing healthcare expenditure and the presence of well-established healthcare infrastructure are also fueling the growth of the overall regional market to a large extent.
Diphenhydramine Market Companies and Competitive Landscape
The diphenhydramine market is moderately competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Thermo Fisher Scientific Inc., Cardinal Health, Pharmaceutical Associated, Bayer AG, Pfizer Inc., Johnson & Johnson, Cigna, Remedy Labs, and Fresenius Kabi. Among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the diphenhydramine market globally.
Thermo Fisher Scientific Inc.
Overview: Founded in 2006 and is headquartered at Waltham, Massachusetts, the U.S.; Thermo Fisher Scientific Inc. is engaged in providing analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery, and diagnostics services under the brands Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services worldwide. The company operates through four business segments, namely, Analytical Instruments, Life Sciences Solutions, Laboratory Products and Services, and Specialty Services. The company provides oligonucleotide products through Invitrogen, under the life Sciences solutions business segment.
With its subsidiaries and strong network of distribution, the company has its presence across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Product Portfolio: The Company’s portfolio comprised its lead Iodine-Water-Pyridine-Tetrahydrofuran Oxidizer Solution (0.02 M), Trifluoroacetic Acid (TFA) Neat Liquid, in addition to Trichloroacetic Acid Dichloromethane, Deblocking Solution targeting high-performance reagents begin with raw materials that must conform to strict specifications.
